Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on June 8, 2022, regarding events occurring on June 3, 2022. The company is incorporated in Delaware and trades on the Nasdaq Global Market under the symbol OCUL.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on executive personnel changes and related compensation arrangements.
Material Changes
- Executive Departure: Michael Goldstein, M.D., President of Ophthalmology and Chief Medical Officer, mutually agreed to depart the company effective June 30, 2022.
- Executive Appointment: Rabia Gurses Ozden, M.D., Senior Vice President of Clinical Development, will assume the role of Chief Medical Officer effective July 1, 2022.
- Consulting Arrangement: Dr. Goldstein will transition to an advisory role under a consulting agreement effective July 1, 2022.
Outlook, Risks, and Unusual Items
Consulting Agreement Terms:
- Duration: The agreement runs from July 1, 2022, to June 30, 2023, with automatic one-year renewals through June 30, 2026, unless terminated.
- Compensation: Dr. Goldstein is entitled to a monthly fee of $6,000, subject to certain adjustments.
- Termination: Either party may terminate without cause upon 30 days' written notice. The company may terminate immediately if Dr. Goldstein fails to execute a separation and release agreement or breaches the contract.
- Restrictions: The agreement includes non-competition and non-solicitation clauses.
Documentation: The full text of the Consulting Agreement is not included in this filing but is expected to be filed as an exhibit to the Form 10-Q for the period ended June 30, 2022.
Investor Verification Checklist
- Verify the execution of the separation and release of claims agreement by Dr. Goldstein to ensure the consulting arrangement remains valid.
- Review the upcoming Form 10-Q for the full text of the Consulting Agreement to understand specific adjustment mechanisms for the $6,000 monthly fee.
- Monitor the transition of clinical development responsibilities from Dr. Goldstein to Dr. Ozden.